FY2025 EPS Estimates for GH Research Reduced by Analyst

GH Research PLC (NASDAQ:GHRS) – HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of GH Research in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.78) per share for the year, down from their prior forecast of ($0.76). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q4 2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($1.02) EPS.

Several other research firms have also issued reports on GHRS. Guggenheim reiterated a “buy” rating and set a $29.00 target price on shares of GH Research in a report on Monday, January 5th. Citigroup reiterated a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Thursday, January 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of GH Research in a research note on Monday, January 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.75.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $15.99 on Thursday. The company’s 50-day moving average price is $15.34 and its two-hundred day moving average price is $14.21. GH Research has a one year low of $7.98 and a one year high of $19.51. The stock has a market capitalization of $831.96 million, a PE ratio of -21.61 and a beta of 1.00.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, March 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06.

Hedge Funds Weigh In On GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stempoint Capital LP acquired a new position in GH Research in the 2nd quarter valued at about $1,229,000. CenterBook Partners LP bought a new stake in shares of GH Research during the third quarter worth approximately $2,376,000. Virtus Investment Advisers LLC bought a new stake in shares of GH Research during the second quarter worth approximately $89,000. HighVista Strategies LLC acquired a new position in shares of GH Research in the second quarter valued at approximately $637,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of GH Research by 631.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 80,986 shares of the company’s stock worth $1,029,000 after purchasing an additional 69,911 shares during the period. 56.90% of the stock is owned by institutional investors.

Key GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: GH Research beat consensus for the quarter, reporting ($0.23) EPS vs. consensus ($0.29), a $0.06 beat — a near‑term fundamental surprise that can support the stock.
• Positive Sentiment: Business update: completed Phase 2b of GH001 for treatment‑resistant depression, presented the full dataset at ASCP and ECNP, and the FDA cleared GH001 for U.S. clinical investigation (enabling U.S. enrollment). The company also reported $280.7M in cash, cash equivalents and marketable securities as of 12/31/25 — these operational and balance‑sheet items materially de‑risk near‑term funding and clinical execution. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: HC Wainwright reaffirmed a Buy and a $70 price target (reported publicly), which supports investor sentiment and provides a high benchmark for upside. GH Research (NASDAQ:GHRS) Price Target Raised to $70.00
• Neutral Sentiment: Short interest data reported is effectively zero and shows no meaningful short‑pressure signal at this time, so it is not a driver of today’s move.
• Negative Sentiment: HC Wainwright reduced several near‑term EPS forecasts (Q4 2025 and FY2025–FY2028/FY2026–FY2027), e.g., FY2026 EPS cut to ($0.96) from ($0.79) and FY2027 to ($1.33) from ($0.84). These downward revisions reflect weaker near‑term profitability expectations and could cap upside until clinical milestones are realized.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.